Myomo (MYO) Non Operating Investment Income (2022 - 2023)

Myomo (MYO) posted Non Operating Investment Income of -$70124.0 for Q3 2023, down 460.36% on a QoQ basis from -$12514.0 in Q2 2023, and down 321.11% year-over-year from $31713.9 in Q3 2022.

Myomo (MYO) Non Operating Investment Income (2022 - 2023) Analysis & Trends

Myomo's Non Operating Investment Income history runs 2 years deep, the most recent figure standing at -$70124.0 for Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn -
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn -
10 Myomo 43.43 Mn 24.46 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 -70,124.00
Sep 30, 2023 -70,124.00
Jun 30, 2023 -12,514.00
Jun 30, 2023 -12,514.00
Sep 30, 2022 -16,652.00
Sep 30, 2022 -16,652.00
Jun 30, 2022 -33,208.00
Jun 30, 2022 -33,208.00